Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among females. BC cells not showing HER-2/Neu amplification and not expressing estrogen/ progesterone receptors are named triple-negative BC (TNBC) cells. TNBC represents 10-15% of all BC and is associated with an aggressive clinical course. TNBC patient prognosis, survival and response to current therapies are poor and for this reason, it is crucial to search for new therapeutic targets in TNBC to develop new therapeutic strategies. One of these targets is the neurokinin-1 receptor (NK-1R). It is well known that the substance P (SP)/NK-1R system is involved in cancer progression. TNBC cells overexpress the NK-1R and, after binding to this receptor, SP promotes the proliferation/ migration of TNBC cells. Non-peptide NK-1R antagonists (e.g., aprepitant) are known to exert, via the NK-1R, an antitumor action; TNBC cells die by apoptosis. In this review, we update the data on a promising therapeutic innovation: the use of NK-1R antagonists for the treatment of TNBC patients.

中文翻译：

---

三阴性乳腺癌：Neurokinin-1受体拮抗剂如何可以用作一种新的治疗方法。

乳腺癌（BC）是女性中最常被诊断出的癌症，也是导致癌症死亡的主要原因。未显示HER-2 / Neu扩增且不表达雌激素/孕激素受体的BC细胞被称为三阴性BC（TNBC）细胞。TNBC占所有BC的10-15％，并且与积极的临床病程有关。TNBC患者的预后，生存率和对当前疗法的反应都很差，因此，在TNBC中寻找新的治疗靶标以开发新的治疗策略至关重要。这些靶标之一是神经激肽1受体（NK-1R）。众所周知，物质P（SP）/ NK-1R系统参与了癌症的发展。TNBC细胞过表达NK-1R，与该受体结合后，SP促进TNBC细胞的增殖/迁移。非肽NK-1R拮抗剂（例如，已知aprepitant）通过NK-1R发挥抗肿瘤作用; TNBC细胞因凋亡而死亡。在这篇综述中，我们更新了有关有前途的治疗创新的数据：使用NK-1R拮抗剂治疗TNBC患者。